Anna K. Nowak
#158,723
Most Influential Person Now
Medical oncologist and researcher
Anna K. Nowak's AcademicInfluence.com Rankings
Anna K. Nowakmedical Degrees
Medical
#3150
World Rank
#3605
Historical Rank
Oncology
#215
World Rank
#223
Historical Rank
Anna K. Nowakphilosophy Degrees
Philosophy
#9065
World Rank
#12565
Historical Rank
Logic
#6062
World Rank
#7543
Historical Rank
Download Badge
Medical Philosophy
Why Is Anna K. Nowak Influential?
(Suggest an Edit or Addition)Anna K. Nowak's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer (2016) (2632)
- Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. (2004) (586)
- Mesothelin-family proteins and diagnosis of mesothelioma (2003) (541)
- Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1 (2003) (448)
- Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. (2003) (433)
- First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial (2021) (377)
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. (2017) (328)
- Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study (2017) (271)
- Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. (2002) (250)
- A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma (2002) (229)
- Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. (2013) (216)
- Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans (2007) (198)
- Taxanes for adjuvant treatment of early breast cancer. (2007) (197)
- The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (197)
- Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. (2015) (176)
- Systemic therapy for advanced hepatocellular carcinoma: a review. (2004) (169)
- The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification (2016) (152)
- Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity (2017) (148)
- Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide (2010) (145)
- Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. (2007) (145)
- The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma (2016) (142)
- Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity (2013) (137)
- Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma (2014) (131)
- New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. (2002) (125)
- Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy (2009) (122)
- Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment (2019) (119)
- Targeting Aggressive Cancer Stem Cells in Glioblastoma (2015) (116)
- A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis (2016) (114)
- Soluble mesothelin-related protein--a blood test for mesothelioma. (2005) (114)
- Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. (2011) (113)
- Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. (2004) (112)
- The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma (2016) (112)
- The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma (2016) (112)
- Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. (2015) (107)
- Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. (2004) (107)
- Caring for someone with high-grade glioma: a time of rapid change for caregivers (2010) (107)
- A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters (2010) (104)
- A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice (2017) (103)
- Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. (2017) (102)
- Combined chemoimmunotherapy of solid tumours: improving vaccines? (2006) (102)
- The information and support needs of patients diagnosed with High Grade Glioma. (2010) (99)
- Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. (2013) (98)
- EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. (2020) (97)
- Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden (2010) (97)
- A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit (2013) (97)
- Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth (2009) (95)
- Chemotherapy and immunotherapy: mapping the road ahead. (2016) (91)
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. (2019) (90)
- Diagnosing cancer in the bush: a mixed-methods study of symptom appraisal and help-seeking behaviour in people with cancer from rural Western Australia. (2013) (83)
- Harnessing the immune response to treat cancer (2010) (81)
- The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (81)
- A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma (2012) (81)
- Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo (2012) (79)
- Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. (2020) (77)
- Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia (2009) (72)
- Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy (2010) (72)
- Fertilisers production from ashes after sewage sludge combustion – A strategy towards sustainable development (2017) (72)
- Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation (2018) (71)
- Patient and caregiver perceptions of communication of prognosis in high grade glioma (2011) (71)
- A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. (2015) (70)
- Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma (2018) (70)
- Whole brain radiotherapy after local treatment of brain metastases in melanoma patients - a randomised phase III trial (2011) (70)
- The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer (2012) (69)
- Tumor‐infiltrating dendritic cells exhibit defective cross‐presentation of tumor antigens, but is reversed by chemotherapy (2015) (62)
- The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. (2015) (60)
- A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC) (2007) (60)
- An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma (2012) (59)
- Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. (2019) (59)
- Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules (2018) (59)
- Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. (2019) (59)
- Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1) (2018) (58)
- Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations (2015) (56)
- Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer (2015) (56)
- The Potential Role of Exercise in Neuro-Oncology (2015) (55)
- Cosmesis and Breast-Related Quality of Life Outcomes After Intraoperative Radiation Therapy for Early Breast Cancer: A Substudy of the TARGIT-A Trial. (2016) (55)
- Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. (2021) (55)
- Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies (2012) (55)
- Use of tamoxifen in advanced‐stage hepatocellular carcinoma (2005) (55)
- The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation (2016) (53)
- Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. (2012) (52)
- Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy (2014) (52)
- Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies (2015) (51)
- Malignant pleural mesothelioma: an update on diagnosis and treatment options (2016) (51)
- Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy (2020) (49)
- A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. (2013) (48)
- Predictors of distress and poorer quality of life in High Grade Glioma patients. (2015) (48)
- Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma (2013) (45)
- Overexpression and altered glycosylation of MUC1 in malignant mesothelioma (2008) (43)
- Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. (2016) (43)
- Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial. (2016) (42)
- ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743 (2020) (42)
- First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. (2022) (40)
- The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates. (2013) (40)
- Distress and psychological morbidity do not reduce over time in carers of patients with high-grade glioma (2017) (40)
- Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group. (2010) (39)
- Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile? (2010) (39)
- Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses (2020) (38)
- Progress in the Management of Malignant Pleural Mesothelioma in 2017 (2018) (38)
- OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result (2018) (37)
- Diagnosing cancer in the bush: a mixed methods study of GP and specialist diagnostic intervals in rural Western Australia. (2013) (37)
- CT, RECIST, and malignant pleural mesothelioma. (2005) (36)
- Do carer’s levels of unmet needs change over time when caring for patients diagnosed with high-grade glioma and how are these needs correlated with distress? (2017) (35)
- Combination immune checkpoint blockade as an effective therapy for mesothelioma (2018) (33)
- Characteristic of wet method of phosphorus recovery from polish sewage sludge ash with nitric acid (2016) (31)
- Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma (2013) (31)
- Contribution of the immune system to the chemotherapeutic response (2011) (31)
- A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. (2018) (31)
- Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group. (2016) (31)
- MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma. (2011) (31)
- Randomized Controlled Trial of Shared Care for Patients With Cancer Involving General Practitioners and Cancer Specialists. (2015) (31)
- Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy (2020) (31)
- Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM) (2008) (30)
- Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen (2015) (29)
- Enhancing the efficacy of immunotherapy using radiotherapy (2020) (29)
- Disease volumes as a marker for patient response in malignant pleural mesothelioma. (2013) (29)
- Current state and future directions of pleural mesothelioma imaging. (2008) (28)
- A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET). (2013) (28)
- PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. (2016) (28)
- Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF) (2019) (26)
- Carers of patients with high-grade glioma report high levels of distress, unmet needs, and psychological morbidity during patient chemoradiotherapy. (2016) (26)
- PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion (2019) (26)
- Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: what makes it worthwhile? (2011) (24)
- DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results. (2018) (24)
- Phosphorus cycle - possibilities for its rebuilding. (2013) (24)
- Observer Variability in Mesothelioma Tumor Thickness Measurements: Defining Minimally Measurable Lesions (2014) (24)
- Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response (2017) (23)
- Cosmetic outcome as rated by patients, doctors, nurses and BCCT.core software assessed over 5 years in a subset of patients in the TARGIT-A Trial (2018) (23)
- State of the Art : Advances in Malignant Pleural Mesothelioma in 2017 (2018) (23)
- Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes (2016) (23)
- The Improving Rural Cancer Outcomes Trial: a cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia (2017) (22)
- The Improving Rural Cancer Outcomes (IRCO) Trial: a factorial cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural patients with cancer in Western Australia: a study protocol (2014) (22)
- The Antioxidants Vitamins A and E and Selenium Do Not Reduce the Incidence of Asbestos-Induced Disease in a Mouse Model of Mesothelioma (2012) (22)
- Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT. (2015) (22)
- Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations (2021) (21)
- Peripheral CD8+ T cell proliferation is prognostic for patients with advanced thoracic malignancies (2013) (21)
- Antiangiogeneic Strategies in Mesothelioma (2020) (21)
- Optimization of Response Classification Criteria for Patients with Malignant Pleural Mesothelioma (2012) (21)
- Imaging in pleural mesothelioma: A review of the 12th International Conference of the International Mesothelioma Interest Group. (2015) (21)
- Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma (2013) (21)
- Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study (2014) (20)
- Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. (2019) (19)
- Protocol for the Care-IS Trial: a randomised controlled trial of a supportive educational intervention for carers of patients with high-grade glioma (HGG) (2015) (19)
- Chemotherapy induced nausea and vomiting--prevention and treatment. (2007) (19)
- Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). (2010) (19)
- Restoration of defective cross-presentation in tumors by gemcitabine (2015) (17)
- Evolving management of low grade glioma: No consensus amongst treating clinicians (2016) (17)
- Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma (2021) (17)
- Intraoperative radiotherapy for early breast cancer: do health professionals choose convenience or risk? (2014) (17)
- Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. (2009) (17)
- Immune checkpoint inhibition for the treatment of mesothelioma (2019) (17)
- Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment (2019) (16)
- Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy? (2014) (16)
- LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. (2017) (15)
- First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality (2015) (15)
- Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma (2017) (15)
- Feasibility Testing and Refinement of a Supportive Educational Intervention for Carers of Patients with High-Grade Glioma — a Pilot Study (2018) (14)
- Multimodality Imaging Review of Malignant Pleural Mesothelioma Diagnosis and Staging. (2011) (14)
- Novel Targeted Therapies and Vaccination Strategies for Mesothelioma (2011) (14)
- Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: evidence from an animal model and a human cohort. (2014) (14)
- Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation. (2015) (13)
- Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. (2019) (13)
- Measuring financial toxicity in Australian cancer patients – Validation of the COmprehensive Score for financial Toxicity (FACT COST) measuring financial toxicity in Australian cancer patients (2021) (13)
- Continuing or ceasing bevacizumab at disease progression: Results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma. (2015) (13)
- A systematic review and meta‐analysis of utility estimates in melanoma (2018) (13)
- Bilateral murine tumor models for characterizing the response to immune checkpoint blockade (2020) (13)
- A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma. (2019) (13)
- LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743 (2021) (12)
- Elderly dendritic cells respond to LPS/IFN-γ and CD40L stimulation despite incomplete maturation (2018) (12)
- Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial. (2017) (12)
- 482 Patient Preferences for Adjuvant Radiotherapy in Early Breast Cancer – an Australian Sub-study of the International TARGIT Trial (2012) (12)
- Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life (2019) (12)
- Immunological checkpoint inhibitors enter adolescence. (2013) (12)
- Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery (2019) (11)
- Experimental and Theoretical Mechanistic Study on the Thermal Decomposition of 3,3-diphenyl-4-(trichloromethyl)-5-nitropyrazoline (2021) (11)
- Current chemotherapeutic treatment of malignant pleural mesothelioma (2004) (11)
- Tamoxifen for hepatocellular carcinoma. (2004) (11)
- The Improving Rural Cancer Outcomes Trial: a cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia (2018) (11)
- Cisplatin and gemcitabine in malignant mesothelioma. (2005) (10)
- Small cell lung cancer presenting with paraneoplastic limbic encephalitis (2011) (10)
- Ongoing clinical trials. (2003) (9)
- An Oasis in the Hospital (2014) (9)
- Exploring sleep disturbance among adults with primary or secondary malignant brain tumors and their caregivers. (2020) (9)
- Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed? (2014) (8)
- Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors (2018) (8)
- A prospective study of surgical patterns of care for high grade glioma in the current era of multimodality therapy (2011) (8)
- Transmission Networks of HCV Genotype 1a Enriched With Pre-existing Polymorphism Q80K Among HIV-Infected Patients With Acute Hepatitis C in Poland (2018) (8)
- Human prefrontal cortex gene regulatory dynamics from gestation to adulthood at single-cell resolution (2022) (8)
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis (2022) (7)
- Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial. (2022) (7)
- Ecotoxicological aspects of the use of parabens in the production of cosmetics (2019) (7)
- ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma. (2017) (7)
- Pathologic considerations and standardization in mesothelioma clinical trials. (2019) (7)
- EGFR mutation testing in NSCLC: Patterns of care and outcomes in Western Australia (2009) (7)
- The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET) (2017) (7)
- Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. (2022) (7)
- Management of Advanced Pleural Mesothelioma-At the Crossroads. (2021) (7)
- 264 POSTER Patient preferences for adjuvant radiotherapy in early breast cancer - an Australian sub-study of the pilot TARGIT study (2006) (6)
- Does CA125 binding to mesothelin impact the detection of malignant mesothelioma? (2013) (6)
- Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used (2021) (6)
- Induction of Tumor Cell Apoptosis In Vivo (2003) (6)
- Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical T (2019) (6)
- Statins Do Not Alter the Incidence of Mesothelioma in Asbestos Exposed Mice or Humans (2014) (6)
- Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity? (2021) (6)
- MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study (2017) (6)
- A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb), in patients with recurrent glioblastoma (GBM). (2017) (6)
- Immunotherapy trials in mesothelioma — promising results, but don’t stop here (2019) (6)
- DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial. (2021) (6)
- Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM) (2019) (6)
- First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. (2022) (6)
- Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters (2017) (6)
- Chemoimmunotherapy: still waiting for the magic to happen. (2014) (6)
- Dietary Vitamin D Supplementation Does Not Reduce the Incidence or Severity of Asbestos-Induced Mesothelioma in a Mouse Model (2014) (5)
- ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION (2019) (5)
- Marked functional improvement after combined chemoradiotherapy for cervical spine glioblastoma causing quadriparesis in an adolescent (2014) (5)
- COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed/platinum therapy. (2014) (5)
- Phase 3 International Trial of Adjuvant Whole Brain Radiotherapy (WBRT) or Observation (OBS) Following Local Treatment of 1-3 Melanoma Brain Metastases (MBMs) (2019) (5)
- Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial (2017) (5)
- Taxanes for adjuvant treatment of early breast cancer. (2019) (5)
- Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action (2022) (5)
- CLIN-ONGOING CLINICAL TRIALS (2012) (5)
- Cosmesis and breast-related quality of life outcomes following intra-operative radiotherapy for early breast cancer - a sub-study of the TARGIT - a trial (2016) (4)
- NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma (2021) (4)
- A meta-analysis of taxanes in adjuvant chemotherapy (ACT) of early breast cancer (EBC) (2007) (4)
- Patients and carers' perspectives of participating in a pilot tailored exercise program during chemoradiotherapy for high grade glioma: A qualitative study. (2021) (4)
- NEURO/MEDICAL ONCOLOGY (2013) (4)
- Dry single-stage method of sodium tripolyphosphate production – technological and economic assessment (2014) (4)
- ACTR-75. A MULTICENTER, 3-ARM, OPEN-LABEL, PHASE IIA CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF TANIBIRUMAB (VEGFR2 MAB), IN PATIENTS WITH RECURRENT GBM ASSESSED WITH K-TRANS AND INITIAL AREA UNDER THE GADOLINIUM CONCENTRATION-TIME CURVE (IAUGC) (2017) (4)
- Malignant Pleural Mesothelioma: Present Status and Future Directions (2017) (4)
- Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice (2022) (4)
- Asbestos exposure: challenges for Australian clinicians (2016) (4)
- P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma. (2016) (4)
- Sleep disturbance in people with brain tumours and caregivers: a survey of healthcare professionals’ views and current practice (2020) (4)
- PathoFusion: An Open-Source AI Framework for Recognition of Pathomorphological Features and Mapping of Immunohistochemical Data (2021) (4)
- PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial (2018) (4)
- Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing (2021) (4)
- Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan (2019) (4)
- Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity (2013) (4)
- Radiotherapy in the management of high‐grade gliomas diagnosed in Western Australia: A patterns of care study (2012) (4)
- Supportive care of patients diagnosed with high grade glioma and their carers in Australia (2022) (4)
- Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain Metastases (2020) (4)
- Cisplatin and pemetrexed synergises with immunotherapy to result in cures in established murine malignant mesothelioma (2008) (4)
- Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy (2022) (3)
- P2.06-025 DREAM - A Phase 2 Trial of DuRvalumab with First Line chEmotherApy in Mesothelioma with a Safety Run In: Topic: Mesothelioma and SCLC (2017) (3)
- Corrigendum to "Fertilisers production from ashes after sewage sludge combustion-strategy towards sustainable development" [Environ. Res. 154 (2017) 171-180]. (2017) (3)
- Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1‐3 tyrosine kinase inhibitor anticancer therapy (2021) (3)
- Management of glioblastoma: an Australian perspective. (2020) (3)
- The role of psychosocial support in the experiences of people living with advanced cancer: A qualitative exploration of patients' perspectives (2020) (3)
- 79 Use of 18F-FDG PET imaging in staging and prediction of survival for malignant pleural mesothelioma (MPM) (2006) (3)
- ACTR-04. RESULTS OF THE INTERIM ANALYSIS OF THE EORTC RANDOMIZED PHASE III CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CO-DELETION, AN INTERGROUP TRIAL (2016) (3)
- S59 Chemo-immunotherapy of mesothelioma: depletion of established, suppressive CD4 T cells is critical to achieving cures in a murine model (2011) (3)
- Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial (2022) (3)
- Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR) (2022) (3)
- Alveolar adenoma of the lung: multidisciplinary case discussion and review of the literature (2020) (3)
- The Ecological Association between Asbestos Consumption and Asbestos-Related Diseases 15 Years Later (2022) (3)
- SPS-7Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial (2017) (3)
- Current Management of Malignant Pleural Mesothelioma (2009) (3)
- Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia (2010) (3)
- Assessment of health‐related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma (2008) (3)
- Response to comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma' (2014) (3)
- Repeatability of Quantitative 18F-FET PET in Glioblastoma (2021) (2)
- Biogenic catalysis in sulphide minerals' weathering processes and acid mine drainage genesis. (2010) (2)
- Oral chemotherapy nurse: A trial position at Sir Charles Gairdner Hospital (SCGH), Perth, Western Australia (2014) (2)
- Phase II trials in mesothelioma: an increasing challenge. (2005) (2)
- A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment. (2011) (2)
- Management of malignant pleural mesothelioma (2007) (2)
- Immune Stimulatory Features of Classical Chemotherapy (2013) (2)
- Taxane containing regimens for the adjuvant treatment of early breast cancer (2003) (2)
- 26PPembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH) (2017) (2)
- Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study. (2014) (2)
- P2.06-026 A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress: Topic: Mesothelioma and SCLC (2017) (2)
- Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol (2021) (2)
- Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol (2020) (2)
- A randomized, placebo-controlled study of amatuximab in combination with pemetrexed and cisplatin (P/C) as front-line therapy for subjects with malignant pleural mesothelioma (MPM). (2016) (2)
- A placebo-controlled trial of Sertraline's effects on symptoms, well-being and survival in advanced cancer: The ZEST Trial (2007) (2)
- Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM). (2016) (2)
- Health-related quality of life (HRQL) before and 1 month after axillary surgery in a randomized trial of sentinel node (SN) biopsy versus axillary clearance (AC): the SNAC Trial. (2004) (2)
- LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study (2021) (2)
- Analysis of sodium tripolyphosphate production processes with a cumulative calculation method (2010) (2)
- Tamoxifen for hepatocellular carcinoma. (2004) (2)
- Understanding sleep disturbance in the context of malignant brain tumors: a qualitative analysis. (2020) (2)
- Characterization of the effect of pleurodesis on FLT and FDG PET/CT imaging in malignant pleural mesothelioma (MPM) (2014) (2)
- Brain cancer patients' levels of distress and supportive care needs over time (2022) (1)
- Palliative care facilitates the preparedness of caregivers for thoracic cancer patients (2022) (1)
- Delineating the Cellular Hierarchy of Glioblastoma and Gliosarcoma for Identification of Therapeutic Targets (2015) (1)
- Evidence Based Medicine - teaching with clinical relevance in an undergraduate medical curriculum (2010) (1)
- Heterogeneity of treatment effects in malignant pleural mesothelioma – Authors' reply (2021) (1)
- Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations (2022) (1)
- Carer preparedness improved by providing a supportive educational intervention for carers of patients with high-grade glioma: RCT results (2023) (1)
- Chromium leaching from mine fillings containing chromium mud (2004) (1)
- Chapter 24 – Immune Stimulatory Features of Classical Chemotherapy (2013) (1)
- Adjuvant chemotherapy (ACT) for early colon cancer (ECC): What do investigators think makes it worthwhile (2004) (1)
- The most troublesome aspects of quality of life for people with advanced cancer in a supportive care trial. (2006) (1)
- MA23.01 Phase II Trial of an Oral FGFR Inhibitor AZD4547 as Second or Third Line Therapy in Malignant Pleural Mesothelioma: Final Results of FRAME Study (2019) (1)
- ACTR-78. TAMIGA: A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CONTINUOUS BEVACIZUMAB THROUGH MULTIPLE LINES OF TREATMENT FOR GLIOBLASTOMA (2017) (1)
- New directions in mesothelioma treatment (2015) (1)
- Sustainable use of sewage sludge ash in fertilisers production-PolFerAsh technology (1)
- Repeatability of image features extracted from FET PET in application to post-surgical glioblastoma assessment (2021) (1)
- Phase Ib study of olinvacimab (O) with pembrolizumab (P) in patients with recurrent glioblastoma (rGBM). (2020) (1)
- PATH-11. PROGNOSTIC SIGNIFICANCE OF EPIGENETIC SUBTYPES AND CpGs ASSOCIATED WITH PROGRESSION TO G-CIMP LOW IN THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON (2020) (1)
- Cosmetic outcome as rated by patients, doctors, nurses and BCCT.core software assessed over 5 years in a subset of patients in the TARGIT-A Trial (2018) (1)
- Effects of Photon Radiation on DNA Damage, Cell Proliferation, Cell Survival, and Apoptosis of Murine and Human Mesothelioma Cell Lines (2022) (1)
- Tamoxifen for hepatocellular carcinoma (Review) (2009) (1)
- Intraoperative radiotherapy for early breast cancer: do health professionals choose convenience or risk? (2014) (1)
- Immune checkpoint inhibitor therapy for malignant pleural mesothelioma. (2021) (1)
- Driving innovation through collaboration: development of clinical annotation datasets for brain cancer biobanking. (2019) (1)
- Bisphosphonates for prevention of bone loss in women with early breast cancer (2009) (1)
- Outcomes from the use of computerized neurocognitive testing in a recurrent glioblastoma clinical trial (2021) (1)
- PEARL: A randomised phase 3 trial of early referral to palliative care (PC) for patients with advanced thoracic malignancies (2018) (1)
- Barriers to managing sleep disturbance in people with malignant brain tumours and their caregivers: a qualitative analysis of healthcare professionals’ perception (2021) (1)
- Voluntary exercise in mesothelioma: effects on tumour growth and treatment response in a murine model (2020) (1)
- CD4+ T cells drive an inflammatory, TNF-α/IFN-rich tumor microenvironment responsive to chemotherapy. (2022) (1)
- 263 Up regulation of PD-L1 on peripheral blood CD3+ T cells predicts poor prognosis in patients with non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR) inhibitors (2015) (1)
- “Who can I ring? Where can I go?” Living with advanced cancer whilst navigating the health system: a qualitative study (2022) (1)
- Comparison of biomass and fossil fuels (2014) (1)
- Bisphosphonates for prevention of bone loss in women with early breast cancer (2009) (1)
- What troubles women starting chemotherapy (CT) for advanced breast cancer (ABC) in a randomized trial? (2004) (1)
- The time taken to complete quality of life questionnaires in an advanced cancer trial. (2006) (1)
- CTNI-23. IDH1/2wt ANAPLASTIC GLIOMAS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL: OVERALL SURVIVAL RELATED TO TREATMENT, MGMT STATUS AND MOLECULAR FEATURES OF GLIOBLASTOMA (2020) (1)
- SIX-WEEK EXERCISE INTERVENTION IN PATIENTS WITH MALIGNANT PLEURAL DISEASE IMPROVES PHYSICAL FUNCTION, MUSCULAR STRENGTH AND APPENDICULAR LEAN MASS (2018) (1)
- PSYCHO-ONCOLOGY AND PALLIATIVE CARE (2017) (1)
- What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry. (2021) (1)
- The role of non-coding RNAs in neuroinflammatory process in multiple sclerosis (2022) (1)
- Transmission Networks of HCV Genotype 1a Enriched With Pre-existing Polymorphism Q80K Among HIV-Infected Patients With Acute Hepatitis C in Poland: Erratum. (2019) (1)
- Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). (2017) (1)
- Patient preferences for adjuvant radiotherapy in early breast cancer are strongly influenced by treatment received through random assignment (2019) (1)
- Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial (2019) (1)
- Phase II trial of BNC105P as second-line chemotherapy for advanced malignant pleural mesothelioma (MPM): Australasian Lung Cancer Trials Group and NHMRC Clinical Trials Centre Collaboration. (2012) (0)
- A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice (2017) (0)
- PREDICTION MODELING USING ROUTINE CLINICAL PARAMETERS TO STRATIFY SURVIVAL IN MESOTHELIOMA PATIENTS UNDERGOING SURGERY (2017) (0)
- Diagnostic ability of miR-19a and Let-7f along with platelet and leukocyte extracellular vesicles in acute ischemic stroke patients (2022) (0)
- Thrombosis-related miR-16-5p predicts the disease severity in patients hospitalised for COVID-19 (2022) (0)
- Autoantibodies may predict the neurological severity of patients with Wilson disease (2022) (0)
- Temporally restricted activation of IFNβ signaling determines response to immune checkpoint therapy (2021) (0)
- Expression Patterns of MiR-125a and MiR-223 and Their Association with Diabetes Mellitus and Survival in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (2023) (0)
- High concentration of symmetric dimethylarginine is associated with low platelet reactivity and increased bleeding risk in patients with acute coronary syndrome. (2022) (0)
- Increased symmetric dimethyl-arginine is a predictor factor of decreased platelet reactivity and increased bleeding risk in patients with acute coronary syndrome (2021) (0)
- NIMG-49. A PROSPECTIVE, MULTI-CENTRE TRIAL OF FET-PET IN GLIOBLASTOMA PATIENTS - THE TROG 18.06 FIG STUDY: KEY ASPECTS OF IMAGING AND RADIATION ONCOLOGY CREDENTIALING (2021) (0)
- Radiology: Nuclear imaging (2016) (0)
- Widespread pulmonary invasion by malignant pleural mesothelioma: an important diagnostic consideration (2020) (0)
- Compliance with reporting guidelines by Australian pathologists: an audit of the quality of histopathology reporting in high-grade glioma. (2016) (0)
- A Multimodality Imaging Review of Malignant Pleural Mesothelioma Assessment (2011) (0)
- Host Tumor-Specific CD8 T Cells Cross-Priming Rather than Cross-Tolerizing Cross-Presentation, Increases Tumor Antigen Induction of Tumor Cell Apoptosis In Vivo (2003) (0)
- Participating in Exercise during Chemoradiotherapy Helps Patients Diagnosed with High Grade Glioma to Feel Stronger and Actively Involved in Their Fight Against Cancer: A Qualitative Study (2017) (0)
- Circulating miRNAs as independent predictors of cardiovascular mortality in patients with type 2 diabetes mellitus (2022) (0)
- Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma (2015) (0)
- Phosphate industry in the balance of sustainable development and circular economy (2019) (0)
- QOLP-23. PHASE II RANDOMISED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ACETAZOLAMIDE VERSUS PLACEBO FOR CEREBRAL OEDEMA IN RECURRENT AND/OR PROGRESSIVE HIGH-GRADE GLIOMA REQUIRING TREATMENT WITH DEXAMETHASONE (2020) (0)
- Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters (2017) (0)
- Barriers and potential solutions to international collaboration in neuro‐oncology clinical trials: Challenges from the Australian perspective (2021) (0)
- Patients’ preferences for adjuvant chemotherapy (ACT) in early colon cancer (ECC): What makes it worthwhile? (2008) (0)
- Diffuse Pleural Mesothelioma (2021) (0)
- The Association Between Levetiracetam Prescription and Psychiatric Referral in High-Grade Glioma Patients - a Pilot Study (2016) (0)
- The development of an open web based resource for answering clinical questions: Catering to geographically dispersed learners, teachers and clinicians (2010) (0)
- Adjuvant chemotherapy (ACT) for early colon cancer (ECC): What do investigators think makes it worthwhile. (2004) (0)
- Diagnosing cancer in the bush: A mixed methods study of diagnostic intervals in people with cancer from rural Western Australia (2012) (0)
- Voluntary exercise in mesothelioma: effects on tumour growth and treatment response in a murine model (2020) (0)
- RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL (2021) (0)
- SLEEP DISTURBANCE AMONG ADULT PATIENTS WITH PRIMARY AND SECONDARY BRAIN TUMORS AND THEIR CAREGIVERS: A CROSS-SECTIONAL STUDY (2017) (0)
- Young adults diagnosed with high grade gliomas: Patterns of care, outcomes, and impact on employment (2019) (0)
- Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM). (2018) (0)
- Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors (2018) (0)
- 68P Evaluation of flat dosing for nivolumab (NIVO) + ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743) (2020) (0)
- Randomized Trial of Whole-Brain Radiation Therapy in Melanoma Brain Metastases: First Interim Analysis (2014) (0)
- The impact of reagents concentration on the efficiency of obtaining high-purity magnesium hydroxide (2020) (0)
- Randomized Trial of Whole-Brain Radiation Therapy in Melanoma Brain Metastases: First Interim Analysis (2014) (0)
- Immunotherapeutic Approaches and Vaccination Strategies (2005) (0)
- Potential role for a novel body composition analysis technique in patients with Malignant Pleural Mesothelioma (2018) (0)
- Test-Retest Repeatability of 18F-FET PET in Small Volumes (2019) (0)
- The effects of epidermal growth factor (EGFR) receptor inhibitors on the immune system in patients with advanced non-small cell lung cancer (NSCLC) (2013) (0)
- Correction to: Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used (2021) (0)
- AGITATION AND BEHAVIOURAL DISTURBANCE IN PATIENTS WITH PRIMARY AND SECONDARY FRONTAL LOBE BRAIN TUMOURS - A CASE SERIES SUGGESTIVE OF EXACERBATION OF ANGER DYSREGULATION SECONDARY TO THE ANTICONVULSANT LEVETIRACETAM (2017) (0)
- 1618PDOverall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM) (2017) (0)
- DNA methylation and survival differences associated with the type of IDH mutation in 1p/19q non-codeleted astrocytomas (2020) (0)
- Must countries shoulder the burden of mesothelioma to ban asbestos? A global assessment (2022) (0)
- PEARL: A randomised phase 3 trial of palliative care early in advanced lung cancers (ALTG/TOGA 13/008). (2022) (0)
- Physical activity and glioma: a case–control study with follow-up for survival (2022) (0)
- NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma (2021) (0)
- The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model (2022) (0)
- Investigation on backfiling compositions on the basis of the flotation waste of the zinc and lead ores (2006) (0)
- CTNI-14. A 3-ARM, PHASE IIA TRIAL OF SAFETY & EFFICACY OF OLINVACIMAB, A MONOCLONAL ANTIBODY TO VEGFR2 IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME WITH IMAGING AND PK/PD ASSESSMENTS: FINAL REPORT (2020) (0)
- A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers (2021) (0)
- Low Dose Fractionated Radiotherapy Alters Tumor Blood Vessel Morphology, Increases CD3+CD8+ T Cell Infiltration to the Tumor, and Sensitizes Mesothelioma to Immune Checkpoint Blockade (2022) (0)
- Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF) (2019) (0)
- P1.09-011 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma (2017) (0)
- A feasibility, safety, and efficacy evaluation of supervised aerobic and resistance exercise for patients with glioblastoma undertaking adjuvant chemoradiotherapy (2023) (0)
- Molecular Determinants of Autoimmunity and Immune Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors (Auto-Check Study) (2019) (0)
- Bereavement outcomes of carers of patients with high grade glioma: Experiences of support before and after the death. (2023) (0)
- Usefulness of medical oncologists' estimates of survival time in people with advanced cancer. (2012) (0)
- Abstract 3292: Neo-antigen specific T cell responses can inform cancer therapy (2020) (0)
- Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers (2022) (0)
- Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study (2023) (0)
- Neurosurgical Issues Related to Bevacizumab Use in the Management of Glioblastoma (2015) (0)
- 170TiPLUME-Meso: Randomised phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM) (2017) (0)
- PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma: Topic: Medical Oncology (2017) (0)
- Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma (2022) (0)
- 196 The current status of mesothelioma clinical trials in Australasia (2006) (0)
- Expression changes of circulating ACE2 regulating-microRNA profiles in patients with COVID-19 during hospitalisation (2022) (0)
- Evaluating the utility of the QUAL-EC in the clinical care of patients with advanced cancer. (2015) (0)
- Neurocognitive outcomes in a phase-3 randomised trial comparing adjuvant whole brain radiotherapy with observation after local treatment of brain metastases in patients with melanoma (2019) (0)
- A Randomised Phase II Study of Carboplatin and Bevacizumab in Recurrent Glioblastoma Multiforme (CABARET STUDY). Cooperative Trials Group For Neuro-Oncology (COGNO) (2012) (0)
- Routinely Collected Clinical And Laboratory Data Can Reliably Predict Longer Survival In Malignant Pleural Mesothelioma (2014) (0)
- Review of the integrated exercise physiology (EP) clinic at a tertiary cancer centre: Experience from the ADEM crosby centre, Sunshine Coast University Hospital (SCUH) (2018) (0)
- Incorporating competing risk theory into evaluations of changes in cancer survival: making the most of cause of death and routinely linked sociodemographic data (2020) (0)
- 53 – Malignant Mesothelioma (2018) (0)
- Principals of Modern Chemotherapy and Endocrine Therapy (2009) (0)
- Malignant mesothelioma (MM) and advanced non-small cell lung cancer (NSCLC) have an equally poor prognosis with a median survival of 8-12 months for patients beginning standard palliative platinum doublet chemotherapy regimens [1-4]. Individual (2013) (0)
- Clinical trials in malignant pleural mesothelioma in Australasia. (2005) (0)
- Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26. (2022) (0)
- Abstract CT007: Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma (2023) (0)
- A CASE SERIES OF LEVETIRACETAM-RELATED PSYCHIATRIC SYMPTOMS (2017) (0)
- Developing an evidence based practice (EBP) learning resource: experiences from UWA (2009) (0)
- An evaluation of the QUAL-EC in the clinical care of patients with advanced cancer. (2017) (0)
- Tumor immunity and immunosurveillance, session 2 (WS-093b) Chairpersons: Takashi Nishimura, Jean-Pierre Abastado (2010) (0)
- Characteristics of the residues after phosphorus recovery from incinerated sewage sludge for the production of building materials (2015) (0)
- Parameters Incorporating Quantitative FDG-PET Imaging with Clinical A Novel Prognostic Model for Malignant Mesothelioma (2010) (0)
- Feasibility and Preliminary Efficacy of a 6-Week Exercise Intervention in Patients with Malignant Pleural Disease (2017) (0)
- For peer review only The IRCO Trial: a factorial cluster -randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia: study protocol. (2014) (0)
- Longitudinal Trajectory of Quality of Life for Patients with Melanoma Brain Metastases: A Secondary Analysis from a Whole Brain Radiotherapy Randomized Clinical Trial (2023) (0)
- Activation of Immune-Mediated Tumor Cell Death by Chemotherapy (2013) (0)
- MicroRNA-223 might be a predictive biomarker for major adverse cardiovascular events prognosis in patients undergoing transcatheter aortic valve implantation procedure (2021) (0)
- INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY (2021) (0)
- Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group (iMig). (2022) (0)
- Fingerprint of novel circulating microRNAs identify patients with stroke-embolic stroke of undetermined source (2021) (0)
- Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial (2018) (0)
- Final Results of the Dream Trial: A Phase 2 Trial of Durvalumab with First-Line Chemotherapy in Mesothelioma with a Safety Run-In (2020) (0)
- Reply to K. Masuda et al. (2019) (0)
- AGOG: Australian Genomics and Clinical Outcomes of Glioma - A World Class Resource for the Braing Tumour Community (2008) (0)
- 11C- Methionine and 18F- Fluorothymidine PET Imaging in Suspected Residual or Recurrent Glioma (2010) (0)
- "You can't ask questions about what you don't know". Determing the needs of patients with high grade gliomas and their carers (2007) (0)
- New and old treatments for malignant mesothelioma: not just immunotherapy. (2021) (0)
- Clinical characteristics of desmoplastic pleural malignant mesothelioma: A case series of 19 patients. (2014) (0)
- Bevacizumab-related Remote Intracranial Hemorrhages After Glioma Resection: A Cautionary Note Regarding the “Safe” Cessation Period (2014) (0)
- What caused your cancer? A survey of patients with early breast and bowel cancer (2008) (0)
- A Twenty Year Audit of the Cytological Diagnosis of Pleural Malignant Mesothelioma (2012) (0)
- Measuring Malignant Pleural Mesothelioma (2019) (0)
- Bilateral murine tumor models for characterizing the response to immune checkpoint blockade (2020) (0)
- OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma: Topic: Medical Oncology (2017) (0)
- Feasibility Testing and Refinement of a Supportive Educational Intervention for Carers of Patients with High-Grade Glioma — a Pilot Study (2017) (0)
- CONFIRMing single-drug immune checkpoint blockade efficacy in mesothelioma. (2021) (0)
- The Improving Rural Cancer Outcomes (IRCO) Trial: a factorial cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia (2017) (0)
- P3.09-004 Routine Clinical Parameters Can Stratify Survival Characteristics in Mesothelioma Patients Undergoing Surgery (2017) (0)
- 234 MUC1 in malignant mesothelioma (2006) (0)
- Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study. (2018) (0)
- Immune marker expression of irradiated mesothelioma cell lines (2022) (0)
- Phase II trial of combined temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. (2010) (0)
This paper list is powered by the following services:
Other Resources About Anna K. Nowak
What Schools Are Affiliated With Anna K. Nowak?
Anna K. Nowak is affiliated with the following schools:
